Cline Scientific to explore a change of listing venue to Nasdaq First North

The board of Cline Scientific AB (“Cline” or “The Company”) has decided to explore the possibility of changing listing venue from Spotlight Stock Market (former Aktietorget) to Nasdaq First North. Nasdaq First North is Nasdaq's European growth market that operates as a multilateral trading venue (MTF), the same as Spotlight Stock Market. The intention is for the move to take place during 2021.

The Board of Cline Scientific makes the assessment that a listing of the Company's shares on Nasdaq First North Growth Market will lead to greater exposure of the business to international investors and partners, a key part of Cline’s upcoming commercial strategy. The listing on the Nasdaq First North Growth Market is also considered to be a seal of quality for potential international investors, partners and suppliers. The listing is thus considered to promote Cline Scientific's future growth and development.

For more information, please contact:
Patrik Sundh, CEO
Email: patrik.sundh@clinescientific.com
Phone: +46 703-585 088

Cline Scientific AB (publ)                                                 Phone: 031-387 55 55
Argongatan 2 C                                                                   Email: info@clinescientific.com
431 53  MÖLNDAL                                                              Website: www.clinescientific.com

About Cline Scientific
Cline Scientific develops advanced cancer diagnostics and regenerative medicine treatments. The company is working heavily with R&D through joint collaborations with pharmaceutical companies and academic researchers around the world. The focus is on projects in the cancer diagnostic and stem cell therapy fields since Clines nanotechnology here provides unmet solutions to critical challenges and functions. The unique patented surface nanotechnology is used in cell-based products and processes to drive projects within Life Science into and through the clinical phase